PPBT Relative Valuation
PPBT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, PPBT is overvalued; if below, it's undervalued.
Historical Valuation
Purple Biotech Ltd (PPBT) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -6.43. The fair price of Purple Biotech Ltd (PPBT) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：2.40
Fair
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
40.64
P/B
Median3y
95.69
Median5y
144.41
-164.56
FCF Yield
Median3y
-109.56
Median5y
-71.24
Competitors Valuation Multiple
The average P/S ratio for PPBT's competitors is 22.35, providing a benchmark for relative valuation. Purple Biotech Ltd Corp (PPBT) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
FAQ
Is Purple Biotech Ltd (PPBT) currently overvalued or undervalued?
What is Purple Biotech Ltd (PPBT) fair value?
How does PPBT's valuation metrics compare to the industry average?
What is the current P/B ratio for Purple Biotech Ltd (PPBT) as of Jul 13 2025?
What is the current FCF Yield for Purple Biotech Ltd (PPBT) as of Jul 13 2025?
What is the current Forward P/E ratio for Purple Biotech Ltd (PPBT) as of Jul 13 2025?